John Markels - Feb 25, 2022 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
Director
Signature
John Markels, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
SGMO
Transactions as of
Feb 25, 2022
Transactions value $
$0
Form type
4
Date filed
3/1/2022, 04:10 PM
Next filing
Jun 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Award $0 +12.5K +94.7% $0.00 25.7K Feb 25, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMO Stock Option (Right to Buy) Award $0 +25K $0.00 25K Feb 25, 2022 Common Stock 25K $5.90 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2 Includes 1,667 shares subject to the Reporting Person's February 11, 2020 RSU grant that will vest in one final annual installment on February 11, 2023, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through such date and subject to acceleration as provided in the 2018 EIP.
F3 The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.